Clinical trials: Cutaneous Melanoma
Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases
Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases
Brain metastases in patients with advanced and metastatic melanoma are a frequent complication and a significant cause of morbidity and mortality in this patient population.
- Trial name
- ENCEFALO (NCT06887088)
- Testing
- Encorafenib + Binimetinib, cemiplimab+fianlimab
- Where
- 18 sites in Spain
- Volunteers
- 33 people
- Sponsor
- Grupo Español Multidisciplinar de Melanoma
Melanoma (Skin)
Skin Health Online for Melanoma: Better Risk Assessment
This study will have two phases, with an added usability test after Phase I and before Phase 2. Phase 1: Cognitive Interviews of materials in Spanish. Phase 2: Personalized Genomic Testing for Skin Cancer (PGT-SC).
- Trial name
- SOMBRA (NCT03130569)
- Testing
- Web-based Module Group
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of New Mexico
Acral Lentiginous Malignant Melanoma, Ciliary Body and Choroid Melanoma, Medium/Large Size
AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
This phase II trial is studying how well AZD2171 works in treating patients with recurrent or stage IV melanoma. AZD2171 may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes…
- Conditions
- Acral Lentiginous Malignant Melanoma, Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma
- Trial name
- NCT00243061
- Testing
- cediranib maleate
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Cutaneous Melanoma, Melanoma
Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma
This pilot phase I trial studies how well sonazoid-enhanced ultrasound works in detecting sentinel lymph node in patients with cutaneous melanoma.
- Trial name
- NCT02968680
- Testing
- Sentinel Lymph Node Biopsy, Ultrasonography, Sonazoid
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Southern California
Recurrent Melanoma, Stage IIIA Melanoma
Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib
This phase II trial studies how well selumetinib and Akt inhibitor MK2206 works in treating patients with stage III or stage IV melanoma who failed prior therapy with vemurafenib or dabrafenib.
- Conditions
- Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma
- Trial name
- NCT01519427
- Testing
- Akt inhibitor MK2206, selumetinib, laboratory biomarker analysis
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Melanoma
Preoperative Planning With PSMA-PET in Melanoma Surgery Trial
This is a non-randomised, single-centre Phase 2 study, investigating whether the diagnostic biomarker, prostate-specific membrane antigen (PSMA), can detect melanoma metastases using PSMA PET/ CT.
- Trial name
- PPPIMS (NCT06560905)
- Testing
- 68Ga-PSMA
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Metastatic Melanoma, Nausea
Nausea and Vomiting In Patients Receiving Consecutive Days of Cisplatin
The purpose of this study is to observe the incidence of nausea with systemic chemotherapy that includes consecutive days (more than one day)of cisplatin medication.
- Trial name
- NCT00716560
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Acute Myeloid Leukemia, Brain Glioblastoma
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
This randomized pilot clinical trial studies health care coach support in reducing acute care use and cost in patients with cancer.
- Conditions
- Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative, Extensive Stage Small Cell Lung Carcinoma
- Trial name
- NCT03154190
- Testing
- Best Practice, Laboratory Biomarker Analysis, Supportive Care
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- Stanford University
Melanoma, Skin Neoplasms
Imatinib Mesylate in Treating Patients With Metastatic Melanoma
RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and may be an effective treatment for metastatic melanoma.
- Trial name
- NCT00027586
- Testing
- Imatinib mesylate (STI571)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Non Small Cell Lung Cancer, Triple Negative Breast Cancer
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors
- Conditions
- Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
- Trial name
- NCT03504488
- Testing
- CAB-ROR2-ADC, PD-1 inhibitor
- Where
- 59 sites in United States, Greece and 4 more
- Volunteers
- 132 people
- Sponsor
- BioAtla, Inc.
Malignant Melanoma
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
This non-interventional study will compare the Cobas BRAF V600 mutation assay with in-house methods used in molecular laboratories for the assessment of the BRAF mutation status in melanoma tumor samples.
- Trial name
- NCT01744860
- Where
- 12 sites in France
- Volunteers
- 420 people
- Sponsor
- Hoffmann-La Roche
Melanoma, Quality of Life
Quality of Life and Surgical Late Effects of Melanoma Treatment
Health-related Quality of life in Danish stage IB-III cutaneous melanoma patients.
- Conditions
- Melanoma, Quality of Life, Lymphedema, Depression
- Trial name
- NCT02352623
- Testing
- DXA scan, Clinical examination
- Where
- Denmark
- Volunteers
- 435 people
- Sponsor
- Herlev Hospital
Metastatic Melanoma
Physical Activity Directly Before Immunotherapy (Nivolumab and Ipilimumab) in Melanoma
The aim of this research project is to determine whether a short bout of physical exercise immediately before the start of immunotherapy (Nivolumab and Ipilimumab) is feasible and has a positive effect on the effectiveness of…
- Trial name
- SPRINT (NCT07564570)
- Testing
- 30 Minutes Cycle Ergometer
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Melanoma and Brain Metastases
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain
This study is designed to assess the efficacy, pharmacokinetics, safety, and tolerability of an oral, twice daily dose of 150 mg GSK2118436 administered to subjects with BRAF V600E or V600K mutation-positive metastatic melanoma…
- Trial name
- Break MB (NCT01266967)
- Testing
- GSK2118436
- Where
- 24 sites in United States, Australia and 4 more
- Volunteers
- 172 people
- Sponsor
- GlaxoSmithKline
Melanoma
Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma
"Elesclomol (STA-4783), N-malonyl-bis (N'-methyl-N'-thiobenzoylhydrazide) is a new chemical entity with a novel structure. STA-4783 induces an oxidative stress response in cells.
- Trial name
- NCT00522834
- Testing
- Elesclomol (STA-4783), Paclitaxel
- Where
- 101 sites in United States, Australia and 6 more
- Volunteers
- 630 people
- Sponsor
- Synta Pharmaceuticals Corp.
Stage IV Melanoma, Recurrent Melanoma
Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma
RATIONALE: Interferon beta may interfere with the growth of tumor cells. PURPOSE: This phase II trial is studying how well interferon beta works in treating patients with metastatic cutaneous (skin) melanoma or ocular (eye)…
- Trial name
- NCT00085306
- Testing
- recombinant interferon beta
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Case Comprehensive Cancer Center
Malignant Melanoma
Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients
vaccination protocol to induce specific immune responses against melanoma associated antigens by intradermal injections of mRNA coding for the corresponding antigen
- Trial name
- NCT00204607
- Testing
- mRNA, GM-CSF s.c.
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital Tuebingen
Solid Tumor, Non Small Cell Lung Cancer
A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
This is an open-label, multicenter, multi-dose escalation and dose expansion study in subjects with selected advanced solid tumors (Part A) and advanced metastatic pancreatic cancer (Parts C \& D) to evaluate the safety and…
- Conditions
- Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- NCT04731467
- Testing
- CM-24 and Nivolumab - Dose Escalation, CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion, CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion
- Where
- 18 sites in United States, Israel and 1 more
- Volunteers
- 79 people
- Sponsor
- Famewave Ltd.
Breast Cancer, Lung Cancer
IDO Inhibitor Study for Relapsed or Refractory Solid Tumors
This study provides an early evaluation of an entirely new class of small molecule agents directed at disruption or elimination of tumor tolerance, a phenomenon now demonstrated to be involved in the growth of many solid tumors.
- Conditions
- Breast Cancer, Lung Cancer, Melanoma, Pancreatic Cancer
- Trial name
- D-1MT (NCT00739609)
- Testing
- 1-methyl-D-tryptophan
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- NewLink Genetics Corporation
Uveal Melanoma
Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma
This is a Phase 2, multi-center, open-label study in patients with surgically incurable stage III or IV uveal melanoma who have not received prior immunotherapy.
- Trial name
- NCT01034787
- Testing
- CP-675,206
- Where
- 3 sites in Canada
- Volunteers
- 11 people
- Sponsor
- AHS Cancer Control Alberta